Lupin has informed about submission of a Press Release as regards receipt of USFDA approval for Potassium Chloride for Oral Solution USP, 20 mEq, to market a generic version of Pharma Research Software Solution LLC's Potassium Chloride for Oral Solution, 20 mEq. It is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.